ADRA2 agonists are believed to reduce mortality related to hyperinflammation and acute respiratory failure in COVID-19 patients, as well as to have immunomodulatory effects by maintaining endothelial junction integrity and reducing immune cell activity even when an inflammatory stimulus is present (Hamilton et al., 2022). Here, ADRA2A is linked to acute respiratory failure.